

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: November 4, 2010 (use as many sheets as necessary)		Application Number	10/536,834		
		Filing Date	03/20/2006		
		First Named Inventor	Steffen GOLETZ, et al.		
		Art Unit	1643		
		Examiner Name	Karen A. Canella		
Sheet	1	of	2	Attorney Docket Number	00056-0001-001

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.†	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code² (if known)			
AA	US 2002/132771		09-19-2002	Madiyalakan	
AB	5,506,343		04-09-1996	Dana-Farber Cancer	
AC	5,683,674		11-04-1997	Imperial Cancer Institute	
AD	5,804,187		09-08-1998	Cancer Research Fund	
AE	6,315,997		11-13-2001	Cancer Research Fund	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.†	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code³ Number⁴ Kind Code⁵ (if known)			
AF	WO 02/44217		06-06-2002	Lo Benny Kwan Ching	
AG	WO 01/12217		02-22-2001	Altarex, Inc.	
AH	WO 93/20841		10-28-1993	Dana-Farber	

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			
AI		Goletz, et al., "Binding Patterns of 33-TD-4(MUC1) Antibodies Towards Single-Chain Fragments and Peptides Mimicking the Conformation of the MUC1 PDTRP EPITOPE", Tumor Biology, Vol. 21, No. Supplement 1, page 142, September 2000.			
AJ		Dai, et al., "Effect of Desialylation on Binding, Affinity, and Specificity of 56 Monoclonal Antibodies Against MUC1 Mucin", Tumor Biology, Vol. 19, Supplemental 19, pages 100-110, 1998.			
AK		Hinoda, et al., "Circulating Tumor-Associated Antigens Detected by Monoclonal Antibodies Against the Polypeptide Core of Mucin: Comparison of Antigen MUSE11 with CA15-3", Gastroenterologia Japonica, Vol. 27, No. 3, pages 390-395, 1992.			
AL		Jensen, et al., "Functional Improvement of Antibody Fragments Using a Novel Phage Coat Protein III Fusion System", Biochemical and Biophysical Research Communications, Vol. 298, pages 566-573, 2002.			
AM		Freshney, "Culture of Animal Cells, A Manual of Basic Technique", Alan R. Liss, Inc., 1983, New York, page 4.			
AN		Dermer, "Another Anniversary for the War on Cancer", Bio/technology, Vol. 12, page 320, 1994.			
AO		MSNBC News Services, "Mixed Results on New Cancer Drug", November 9, 2000.			

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST-16 if possible. 6 Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1480, Alexandria, VA 22313-1480.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1448/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: November 4, 2010 (use as many sheets as necessary)		Application Number	10/536,834
		Filing Date	03/20/2006
		First Named Inventor	Steffen GOLETZ, et al.
		Art Unit	1643
		Examiner Name	Karen A. Canelia
Sheet	2	of	2
		Attorney Docket Number	00056-0001-001

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T*
	AP	Gura, "Systems for Identifying New Drugs are Often Faulty", Science, Vol. 278, pages 1041-1042, 1997.	
	AQ	Wu, et al., "Humanization of a Murine Monoclonal Antibody by Simultaneous Optimization of Framework and CDR Residues", Journal of Molecular Biology, Vol. 294, pages 151-162, 1999.	
	AR	Burgess, et al., "Possible Dissociation of the Heparin-Binding and Mitogenic Activities of the Heparin-Binding (Acidic Fibroblast) Growth Factor-1 from its Receptor Binding Activities by Site Directed Mutagenesis of a Single Lysine Residue", Journal of Cell Biology, Vol. 111, pages 2129-2138, 1990.	
	AS	Lazar, et al., "Transforming Growth Factor Alpha: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities", Molecular and Cellular Biology, Vol. 8, pages 1247-1252, 1988.	
	AT	Fiebig, et al., "Clonogenic Assay with Established Human Tumor Xenografts: Correlation of In Vitro to In Vivo Activity as a Basis for Anticancer Drug Discovery", European Journal of Cancer, Vol. 40, pages 802-820, 2004.	
	AU	Scheibel, et al., "Contribution of N- and C-Terminal Domains to the Function of Hsp90 in Saccharomyces Cerevisiae", Molecular Microbiology, Vol. 34, pages 701-713, 1999.	
	AV	Skerra, et al., "Alternative Non-Antibody Scaffolds for Molecular Recognition", Current Opinion in Biotechnology, Vol. 18, pages 295-303, 2007.	
	AW	Hosse, et al., "A New Generation of Protein Display Scaffolds for Molecular Recognition", Protein Science, Vol. 15, pages 14-27, 2006.	
	AX	Hufton, et al., "Development and Application of Cytotoxic T Lymphocyte-Associated Antigen 4 as a Protein Scaffold for the Generation of Novel Binding Ligands", FEBS Letters, Vol. 475, Issue 3, pages 225-231.	
	AY	Nicaise, et al., "Affinity Transfer by CDR Grafting on a Nonimmunoglobulin Scaffold", Protein Science, Vol. 13, pages 1882-1891, 2004.	
	AZ	Peach et al., "Complementarity Determing Region 1 (CDR1)- and CDR3-analogous Regions in CTLA-4 and CD28 Determine the Binding to B7-1", Journal of Experimental Medicine, Vol. 180, pages 2049-2058.	
	BA	Saerens, et al., "Identification of a Universal VHH Framework to Graft Non-Canonical Antigen-Binding Loops of Camel Single-Domain Antibodies", Journal of Molecular Biology, Vol. 352, Issue 3, pages 597-607, September 2005.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1480, Alexandria, VA 22313-1480.

If you need assistance in completing the form, call 1-800-PTO-6100 (1-800-786-6100) and select option 2.